Treats Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive. ANDA 206251, held by Accord Hlthcare. Aripiprazole.
As of Nov 16, 2026, ANDA 206251 (Aripiprazole), held by Accord Hlthcare, was first approved by FDA on Dec 7, 2016, with 0 approved supplements and 0 published complete response letters.
Aripiprazole tablets are indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette's Disorder Aripiprazole is an atypical antipsychotic. Aripiprazole is indicated for: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette's Disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 7, 2016 | Original application | Approved |
| Aripiprazole2MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole5MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole10MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole15MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole20MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole30MG · tablet;oral | Aripiprazole | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters